Evidence map›Paper›PMID 41279209›Full record

ArticlebioRxiv : the preprint server for biology2025

Inflammatory Biomarkers of Asymptomatic and Symptomatic Tuberculosis.

Denis Awany, Dominique T Ariefdien, Simon C Mendelsohn, Virginie Rozot, Humphrey Mulenga, Sarah Nyangu, Michele Tameris, Tumelo Moloantoa, Austin Katona, Fernanda Maruri and 24 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors.

Denis AwanySouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Dominique T AriefdienSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Simon C MendelsohnSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Virginie RozotSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Humphrey MulengaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Sarah NyanguSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Michele TamerisSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Tumelo MoloantoaPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Austin KatonaVanderbilt Tuberculosis Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Fernanda MaruriVanderbilt Tuberculosis Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Firdows NoorSouth African Medical Research Council Centre for TB Research; Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Ravindre PanchiaPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Khuthadzo HlongwanePerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Kim StanleySouth African Medical Research Council Centre for TB Research; Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Yuri F van der HeijdenVanderbilt Tuberculosis Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Katie HadleySouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Andrew-Fiore GartlandVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Craig InnesThe Aurum Institute, Johannesburg, South Africa.
William BrumskineVanderbilt Tuberculosis Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Keertan DhedaCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute and South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.
Shameem JaumdallyCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute and South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.
Tahlia PerumalCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute and South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.
Neil MartinsonPerinatal HIV Research Unit, University of Witwatersrand, Johannesburg, South Africa.
Al LeslieAfrica Health Research Institute, Durban, South Africa.
Bernard FourieDepartment of Medical Microbiology, University of Pretoria Faculty of Health Sciences, Pretoria, South Africa.
Andriëtte HiemstraSouth African Medical Research Council Centre for TB Research; Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Stephanus T MalherbeSouth African Medical Research Council Centre for TB Research; Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Gerhard WalzlSouth African Medical Research Council Centre for TB Research; Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Kogieleum NaidooCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Gavin ChurchyardThe Aurum Institute, Johannesburg, South Africa.
Novel N ChegouSouth African Medical Research Council Centre for TB Research; Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Timothy R SterlingVanderbilt Tuberculosis Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Mark HatherillSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.

Funding

Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb)U01AI152075 · NIAID · STELLENBOSCH UNIVERSITY · PI BELISLE, JOHN T, SUTHERLAND, JAYNE · 2020 to 2025
$7.1M
NIAID NIH HHS U01 AI152075
6 · The paper itself

Abstract

A large proportion of individuals with tuberculosis (TB) are asymptomatic. The biological and inflammatory underpinnings of asymptomatic TB are unknown and may differ from symptomatic TB. We characterised blood transcriptomic and proteomic profiles in South African community screening vs. health facility-based triage cohorts. Asymptomatic TB shared core transcriptomic and proteomic features with symptomatic TB, including upregulation of innate, interferon and inflammatory pathways and downregulation of T and B cell pathways. Integration of transcriptomic and proteomic data from asymptomatic TB individuals identified two distinct sub-clusters characterized by higher or lower bacterial burden, blood IFN-γ responses, BMI, and chest radiographic abnormalities, suggesting different disease severity. We identified a new blood transcriptomic signature of asymptomatic TB. However, diagnostic performance of transcriptomic and proteomic markers was weaker for asymptomatic TB than symptomatic TB, suggesting that policy development for community-based, asymptomatic TB screening should not adopt biomarkers developed for symptomatic TB triage without further optimization.

Indexed as

asymptomaticbiomarkerproteomictranscriptomictuberculosis

Identifiers

PMID41279209
PMCPMC12636496

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.